2024-09-21 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing therapies for serious diseases.

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):** VRTX has outperformed the S&P 500, with a cumulative return of 178.73% compared to 133.16% for VOO.  This represents a divergence of 45.57%, which is in the 77.9th percentile of historical divergence, indicating a strong relative performance compared to the broader market.

2. **Recent Price Movement:**
    * **Closing Price:** $479.14
    * **5-day Moving Average:** $481.99
    * **20-day Moving Average:** $479.95
    * **60-day Moving Average:** $481.99
    The stock price is slightly below its 5-day and 60-day moving averages, suggesting a potential short-term downward trend. However, it is trading close to its 20-day moving average, indicating a neutral short-term outlook.

3. **Technical Indicators:**
    * **RSI:** 40.95 (below 50, suggesting the stock is oversold)
    * **PPO:** 0.05 (positive value, indicating a potential upward trend)
    * **Delta_Previous_Relative_Divergence:** -5.4 (negative, suggesting a potential short-term downtrend)
    * **Expected_Return:** 17.79% (potential return over the next 5-10 years based on current investment)

4. **Recent Earnings and Outlook:**
    | Date | EPS | Revenue |
    |---|---|---|
    | 2024-08-02 | -13.92 | 2.65 B$ |  **Missed analyst expectations of -1.65 EPS**
    | 2024-05-07 | 4.26 | 2.69 B$ |  **Beat analyst expectations of 3.91 EPS**
    | 2023-11-07 | 4.01 | 2.48 B$ |  **Beat analyst expectations of 3.86 EPS**
    | 2023-08-02 | 3.55 | 2.49 B$ |  **Beat analyst expectations of 3.42 EPS**
    | 2024-08-02 | 3.55 | 2.49 B$ |  **Beat analyst expectations of 3.42 EPS**

The most recent earnings report for Q2 2024 showed a significant miss on EPS expectations. This could indicate potential challenges in the company's short-term performance. However, the company has a history of strong revenue growth and has beaten earnings estimates consistently in previous quarters. 

**Overall Analysis:**

Vertex Pharmaceuticals Inc. (VRTX) exhibits a strong long-term track record, exceeding the market performance of the S&P 500.  However, recent earnings indicate a potential short-term challenge. Technical indicators suggest a potential short-term downtrend, with an oversold condition reflected in the RSI. However, a positive PPO and a high expected return indicate potential for growth in the long term. Investors should carefully analyze recent earnings reports and the company's future growth strategies before making any investment decisions. 
